Lasangi Dhanapalamudiyanselage

Mrs. Lasangi Dhanapalamudiyanselage

UNIVERSITY OF CONNECTICUT, STORRS, CT 06269
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2020 in Biosensors
Verified
Journal Article
Open access
PDF file
Lasangi DhanapalamudiyanselageLasangi Dhanapalamudiyanselage
Lasangi Dhanapalamudiyanselage
CKColleen Krause
Colleen Krause
AJAbby Jones
Abby Jones
James RuslingJames Rusling
James Rusling
Medical diagnostics is trending towards a more personalized future approach in which multiple tests can be digitized into patient records. In cancer diagnostics, patients can be tested for individual protein and genomic biomarkers that detect cancers at very early stages and also be used to monitor cancer progression or remission during therapy. These data can then be incorporated into patient records that could be easily accessed on a cell phone by a health care professional or the patients themselves on demand. Data on protein biomarkers have a large potential to be measured in point-of-care devices, particularly diagnostic panels that could provide a continually updated, personalized record of a disease like cancer. Electrochemical immunoassays have been popular among protein detection methods due to their inherent high sensitivity and ease of coupling with screen-printed and inkjet-printed electrodes. Integrated chips featuring these kinds of electrodes can be built at low cost and designed for ease of automation. Enzyme-linked immunosorbent assay (ELISA) features are adopted in most of these ultrasensitive detection systems, with microfluidics allowing easy manipulation and good fluid dynamics to deliver reagents and detect the desired proteins. Several of these ultrasensitive systems have detected biomarker panels ranging from four to eight proteins, which in many cases when a specific cancer is suspected may be sufficient. However, a grand challenge lies in engineering microfluidic-printed electrode devices for the simultaneous detection of larger protein panels (e.g., 50–100) that could be used to test for many types of cancers, as well as other diseases for truly personalized care.

1 May 2019 in ECS Meeting Abstracts
Verified
Journal Article
Closed access
AJAbby L Jones
Abby L Jones
Lasangi DhanapalamudiyanselageLasangi Dhanapalamudiyanselage
Lasangi Dhanapalamudiyanselage
TBThaisa Baldo
Thaisa Baldo
MSMohamed Sharafeldin
Mohamed Sharafeldin
CKColleen E. Krause
Colleen E. Krause
James RuslingJames Rusling
James Rusling
Prostate cancer treatment has risk associated with patients’ being overdiagnosed leading to an overtreatment epidemic. In the United States 1 in 9 males are diagnosed with prostate cancer with approximately 10% of these patients having aggressive forms usually requiring surgery. To diagnose these patients, physicians most often rely on the Prostate Specific Antigen (PSA) blood test and the digital rectal exam. PSA is currently the only biomarker approved for prostate cancer diagnostics, but cannot discern cancer from other prostate conditions, such as Benign Prostatic Hyperplasia (BPH) or Prostatitis. Most importantly, PSA cannot identify the aggressive forms of prostate cancer. These inaccuracies lead to unnecessary treatments including surgery of indolent prostate cancer patients that adversely affect the patients’ quality of life. Measurements of small panels of molecular biomarkers in serum holds tremendous potential for cancer diagnostics and personalized therapy. We are evaluating a new protein panel for prostate cancer including PSA, CD-14, ERG, GOLM-1, PEDF-1, IGF-1, VEGF-D and IGFBP-3 that may be indicative of prostate cancer or cancer progression. We designed a microfluidic immunoarray that features miniaturisation, low sample volume, sensitivity adjustable to the sample characteristics, rapid analysis, and low reagent consumption. A protocol was developed for the simultaneous assay of this 8-protein panel in serum that features online capture and detection with a semi-automated multiple protein immunoarray. A nanostructured sensor array with bound capture antibody in the microfluidic device captures the biomarker proteins from the sample, and a sandwich immunoassay is completed following a concurrent injection of target protein standards or sample, biotinylated secondary antibody and polymerized horseradish peroxidase into the detection chamber. Ultra-low limits of detection (LOD) in the sub fg ml-1 range were achieved for the proteins in the panel. Using this strategy, 8-16 proteins can be detected simultaneously within 30 minutes. Measurements of the biomarker panel tested with prostate cancer patient samples and statistical analyses to assess diagnostic utility will be described.

1 May 2019 in ECS Meeting Abstracts
Verified
Journal Article
Closed access
Lasangi DhanapalamudiyanselageLasangi Dhanapalamudiyanselage
Lasangi Dhanapalamudiyanselage
AJAbby L Jones
Abby L Jones
James RuslingJames Rusling
James Rusling
Over-expression of Parathyroid hormone-related peptide (PTHrP) is recognized as the main causative agent of the paraneoplastic syndrome, humoral hypercalcemia of malignancy (HHM). PTHrP is known to be indicative of progression and metastasis of several human cancers. The established prognosis method of PTHrP, immunoradiometric assay (IRMA), is unable to determine the peptide levels prior to the advancement of hypercalcemia due to insufficient sensitivity. Prostate specific antigen (PSA) is a biomarker that has been extensively used as a diagnostic tool in prostate cancer. Unfortunately, PSA is limited in its’ inability to distinguish cancer from other prostate conditions such as Benign Prostatic Hyperplasia (BPH) or Prostatitis. These inaccuracies lead to unnecessary treatments including surgery on indolent cancer patients that adversely affect the patients’ quality of life. Therefore, there is strong appeal for the development of ultrasensitive, low cost multiplexed detection of appropriate biomarkers in clinically relevant ranges to assist the diagnosis and progression of cancers. Here we have employed a lab-developed microfluidic immunoarray for small samples, that features automation, miniaturisation, sensitivity adjustable to the sample characteristics, rapid analysis, and low reagent consumption for the detection of PTHrP and PSA in human cancer patient serum. The immunoarrays employ nanostructured sensors decorated with capture antibodies to perform a sandwich immunoassay using poly-horseradish peroxidase (poly-HRP) with about 80 HPRs per molecule that links to a secondary antibody bound to analytes on the sensor for high sensitivity detection. Incubation times were tailored to obtain limits of detection (LOD) in sub-fg mL-1 without a significant compromise in sensitivity leading to a simple, quick cancer diagnostics and personalized cancer therapy strategies. This may be able to transform the current methods of prostate cancer diagnosis. This system will be utilized to evaluate PTHrP peptides as aggressive prostate cancer biomarkers by analysis of human serum samples from patients.

1 May 2020 in ECS Meeting Abstracts
Verified
Journal Article
Closed access
James RuslingJames Rusling
James Rusling
MSMohamed Sharafeldin
Mohamed Sharafeldin
TCTianqi Chen
Tianqi Chen
AJAbby L Jones
Abby L Jones
Lasangi DhanapalamudiyanselageLasangi Dhanapalamudiyanselage
Lasangi Dhanapalamudiyanselage
Accurate, sensitive measurements of proteins are crucial for modern biomedical research, with applications in basic research, medical diagnostics, therapy guidance, and drug development. Fast, selective, low cost detection of multiple proteins is important for public health and a key component of future personalized medicine. There are >50,000 gene product proteins (omitting post-translational modifications and IgGs) in human plasma, and large subsets in serum, urine, and saliva. However, techniques such as LC-MS/MS, immunoassays and protein counting can reliably detect <2000 of these proteins and are quite expensive. This paper addresses the challenge to develop low cost, automated 3D-printed immunoarrays for liquid protein samples and cells with LODs <0.1 fg/mL. We have developed prototype multiplexed microfluidic immunoarrays with sensitivity better than protein counting applicable to plasma, serum, saliva, urine, cell lysates and cell cultures. Protein detection at the single cell level was also achieved. Unique detection features including nanostructured sensing, array design, and protocol optimization provide large decreases in LODs and greatly enhanced sensitivities. Our prototypes are based on chemiluminescence (CL) and amperometric detection. Our CL array achieved LODs of 0.1 fg/mL for membrane protein DSG3, as well as VEGF-C and VEGF-D in conditioned media of cell cultures. This LOD is 0.8 zeptomolar, or ~100 molecules of DSG3 in 90 mL and results from 30 trillion capture antibodies (Ab1) in array detection cylinders using an ultrabright femto-luminol CL reagent activated by H2O2 and poly-(horseradish peroxidase) (poly-HRP, 400 HRPs/molecule). Femto-luminol combined with poly-HRP provides very high CL signal amplification and S/N using the 400 HPR polymer.Proteins are also efficiently captured in detection cylinders with 30 trillion antibodies, combined with the ultrabright CL reagent and rigorous protocol optimization to prove unprecedented LODs. Microprocessor automation can achieve fast multiplexed assays with these immunoarrays at <$0.50/protein. We are also exploring ultra-high sensitivity amperometric detection in these systems with similar sensitivity enhancement principles.

1 May 2020 in ECS Meeting Abstracts
Verified
Journal Article
Closed access
Lasangi DhanapalamudiyanselageLasangi Dhanapalamudiyanselage
Lasangi Dhanapalamudiyanselage
James RuslingJames Rusling
James Rusling
AJAbby L Jones
Abby L Jones
By 2019, one in every 5 men diagnosed with cancer carry prostate malignancy. Despite being the most frequent form of cancer among American men, prostate cancer still lacks proper diagnostic tools to identify indolent and aggressive forms. Drawbacks in current screening methods such as Prostate Specific Antigen (PSA) test and Digital Rectal Exam have led to over diagnosis and over treatment of prostate cancer, adversely affecting the patient’s quality of life. Herein, we report a simple, inexpensive electrochemical immunoarray for multiplexed detection of a panel of prostate cancer biomarkers, Prostate Specific Antigen (PSA), Vascular Endothelial Growth Factor-D (VEGF-D), Gene fusion proteins ETS related gene(ERG) and Insulin-like Growth Factor-1(IGF-1) that we have verified as providing a more accurate diagnosis of the type of prostate cancer than PSA test alone. The sensor features an array of eight screen printed carbon electrodes (diameter ~700 μm) coated with a layer of 5 nm Au nanoparticles and immobilized with antibodies to capture analytes. After sample introduction and analyte binding, a mixture of poly-horseradish peroxidase (HRP)-labeled detection antibodies are delivered, followed by hydroquinone (HQ) mediator to facilitate amperometric detection. Dual amplification by H2O2-driven oxidation of each of the 400 HRPs iron hemes in poly-HRP labels to Fe=O for amperometric reduction using electron transfer catalysis by HQ along with careful optimization of antibody levels enabled ultra-sensitive detection of the biomarkers with limits of detection (LOD) at ag mL-1 levels with up to 6 log-decades dynamic range. Immunoarray analyses of sera from patients who have undergone prostatectomy and may have very low levels of these biomarkers was explored as a possible test for recurrence of prostate cancer after surgery.